Camp4 Therapeutics Files 8-K
Ticker: CAMP · Form: 8-K · Filed: Oct 1, 2025 · CIK: 1736730
Sentiment: neutral
Topics: financial-statements, exhibits, disclosure
TL;DR
Camp4 Therapeutics filed a routine 8-K on Oct 1, 2025, mostly about financials/exhibits.
AI Summary
On October 1, 2025, Camp4 Therapeutics Corp. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather than a significant event. The company is incorporated in Delaware and headquartered in Cambridge, MA.
Why It Matters
This 8-K filing serves as a standard disclosure for Camp4 Therapeutics Corp., providing updates on financial statements and exhibits. Investors should review the details within the filing for any specific operational or financial information.
Risk Assessment
Risk Level: low — This filing appears to be a routine disclosure of financial statements and exhibits, with no immediate indication of significant operational changes or financial distress.
Key Players & Entities
- Camp4 Therapeutics Corp. (company) — Registrant
- October 1, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Cambridge, MA (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Camp4 Therapeutics Corp.?
The primary purpose of this 8-K filing is to report on Financial Statements and Exhibits, as well as a Regulation FD Disclosure.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 1, 2025.
In which state is Camp4 Therapeutics Corp. incorporated?
Camp4 Therapeutics Corp. is incorporated in Delaware.
What is the business address of Camp4 Therapeutics Corp.?
The business address of Camp4 Therapeutics Corp. is One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA 02139.
What is the telephone number for Camp4 Therapeutics Corp.?
The telephone number for Camp4 Therapeutics Corp. is (617) 651-8867.
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-10-01 08:25:59
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share CAMP The Nasdaq Global Market
Filing Documents
- camp-20251001.htm (8-K) — 26KB
- a20251001exhibit991.htm (EX-99.1) — 16KB
- 0001736730-25-000074.txt ( ) — 170KB
- camp-20251001.xsd (EX-101.SCH) — 2KB
- camp-20251001_lab.xml (EX-101.LAB) — 24KB
- camp-20251001_pre.xml (EX-101.PRE) — 14KB
- camp-20251001_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 1, 2025, CAMP4 Therapeutics Corporation (the "Company") issued a press releases titled "CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01," a copy of which is furnished as Exhibit 99.1 hereto. The information responsive to Item 7.01 of this Form 8-K and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by CAMP4 Therapeutics Corporation on October 1, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CAMP4 THERAPEUTICS CORPORATION By: /s/ Kelly Gold Name: Kelly Gold Title: Chief Financial Officer Date: October 1, 2025